TOCILIZUMAB

tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $200.71 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma
tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: First continuing treatment

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Subsequent continuing treatment

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Balance of supply - Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $200.71 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma
tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: First continuing treatment

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Subsequent continuing treatment

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Balance of supply - Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $217.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma
tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $217.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma
tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $217.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma
tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $200.71 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma
tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $217.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma
tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $200.71 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma
tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Public
S100 HSD Public
Authority Required (STREAMLINED)

Restriction (Streamlined authority code: 17707)

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $200.71 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma
tocilizumab 200 mg/10 mL injection, 10 mL vial
Manner of administration:Injection
Private
S100 HSD Private
Authority Required (STREAMLINED)

Restriction (Streamlined authority code: 17713)

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $217.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma